پ - لنارد
چکیده:
سیوه سال پیش، گادوان و پیکاری گیرنده‌های سروتونین این‌لوم‌های خوک‌هه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ه‌ر

کلید واژه‌ها: ۱- سروتونین ۲- زیگر‌ونه‌های گیرندگی ۳- خواب ۴- اختلالات اضطرابی

بخش پاراماسکولوژی، کالج دانشگاه‌گالری، ایران
سال سوم/ شماره ۱ و ۲/ بهار و تابستان ۱۳۷۵

183

مجله دانشگاه علوم پزشکی ایران
SROTECER RECEPTORS AND THEIR POSSIBLE FUNCTION IN
THE BRAIN

ABSTRACT

Thirty-three years ago, Gaddum and Picarelli classified the
serotonin receptors in the guinea pig ileum into D and M types based
on the activity of dibenzylcine (D) and morphine (M) to block
contractions of intestinal smooth muscle caused by serotonin. The
subsequent location of specific ligand binding sites for serotonin in
the brain has led to the identification of ten serotonin receptor
sub-types in rat brain. The cloning of these receptor sub-types has
been of importance in enabling them to be classified as specific
protein molecules encoded by specific genes. The problem now arises
with regard to the linking of the changes in the cellular activity of the
various receptor sub-types with the plethora of behavioural changes
that arise as a consequence of the actions of serotonin in the brain.

The present review summarizes the evidence implicating the role
of specific serotonin receptor sub-types in sleep, anxiety states,
schizophrenia and depression. A summary of the relationship
between these receptor sub-types and their possible involvement in
the aetiology of these diseases is also given.

Keywords: 1) Serotonin 2) Receptor subtypes 3) Sleep
4) Anxiety disorder 5) Depression

INTRODUCTION

Over a century ago, a substance was recognized in clotted blood which was found
to cause vasoconstriction. This substance was still present following adrenalectomy
therapy suggesting that it differed from

* Pharmacology Department, University College, Galway, Ireland

adrenaline and noradrenaline. Eventually, Rapaport, Green and Page in 1947, purified the vasoconstrictor factor from serum and identified it as serotonin ("serum tonic"). Independently of the American investigators, Erspamer and colleagues in Italy had identified a substance they termed "enteramine" from the intestine. "Enteramine" was subsequently found to be identical to serotonin (25) and was subsequently synthesized by Hamlin and Fisher in 1951. Chemically, serotonin or enteramine is the indoleamine 5-hydroxytryptamine (5-HT).

Following the isolation and synthesis of serotonin in the early 1950's, there has been increasing interest in the physiological function of this amine. Initially it was assumed that its main function was that of a peripheral hormone because of the relatively high concentrations that were found in the gastrointestinal tract and blood. Twarog and page (67) soon showed, however, that it was also present in the mammalian brain thereby suggesting that it may have a neurotransmitter role there (2). Interest in the physiological role of serotonin in the central nervous system has pre-occupied neurobiologists since that time.

The detection of serotonin in nervous and non-nervous tissue was aided by the development of the falk-Hillarp histochemical technique, a method whereby freeze-dried sections of tissue, when exposed to formaldehyde, vapour causes indoleamines to emit a yellow fluorescence. Dahlstrom and Fuxe (16) used this technique to show that highest concentration of serotonin in the brain is located in the raphe nuclei, projections from these cell bodies ascending to the forebrain via the medial forebrain bundle. Descending fibres were also shown to project to the dorsal and lateral horns and the intermediolateral column of the spinal cord.

Detailed observation of the distribution of the serotonergic system in the brain became possible with the development of specific antibodies to the amine (64) and the introduction of autoradiographic methods for both the human (35) and rodent (58) brain.

For serotonin to be considered as a neurotransmitter, it was essential to establish that it produced its physiological effects by activating specific receptors located on the intestinal wall, platelet membrane or on nerve cells. A major development occurred in 1957 when Gaddum and Picarelli (26) showed that the action of serotonin on the guinea pig ileum could be blocked by either phenoxybenzamine (dibenzyline) or morphine.

These investigators termed the two types of serotonin receptors on the intestinal wall "D" (for dibenzyline) or "M" (morphine) receptors, the "M" type receptors being associated with the nerves supplying the intestine that produced contraction of the
smooth muscle by facilitating acetylcholine release while the "D" receptors were located on the smooth muscle wall. More recently, it has been realized that the "D" receptors are widely distributed in the body and coincide with 5HT2 receptors which, when activated by selective agonists, contract smooth muscle and aggregate platelets. They also occur in synaptosomal membranes where they are possibly associated with post-synaptic membrane structures (24). By contrast, the "M" receptor has not been unequivocally identified in neuronal membranes. However, increasing evidence now suggests that the peripheral "M" receptor is identical to the 5HT3 receptor in the brain (6). Thus in a period of some 20 years, the distribution of serotonin in both nervous and non-nervous tissue has been determined, many of its physiological properties explained and the types of receptors upon which it acts to produce its diverse physiological effects evaluated.

5-HT Receptor SUB-TYPES

Current knowledge of 5HT receptors has been derived from advances in medicinal chemistry, form the synthesis of ligands that show considerable specificity for sub-population of 5HT receptors. The application of such ligands to our understanding of the distribution of the 5HT receptor sub-types has been largely due to quantitative invtro autoradiographic emiss-

Sesationin receptors and their possible ......
Serotonin receptors and their possible .......... B.E. Leonard

are attached have shown that the 5HT1-like, 5HT2 and 5HT4 receptors belong to the G protein coupled receptor superfamily, whereas the 5HT3 receptor belongs to the same family as the nicotinic, GABA-A and glycine receptors which are ion gated channel receptors.

The most recent publication of the IUPHAR Commission has re-defined the 5HT receptor subtypes according to their second messenger associations and thereby helped to stress the functional role of the receptor sub-types rather than relying primarily on the specificities of ligands that bind to them (39). This approach has led to the classification of 5HT receptors into those linked to adenylate cyclase (5HTIA, 5HTIB, 5HTID, 5HT4), those linked to the phosphatidyl inositol system (5HT2A, 5HT2B and 5HT2C), and those linked directly to ion channels (5HT3). Table 1 summarizes the accepted classification of the 5HT receptor sub-types together with their anatomical location and the most specific agonists and antagonists which have been developed.

More recently the family of 5HT receptors has been dramatically increased to include 5TH4, 5HT5A and 5B, 5HT6 and 5HT7. Of these, only the 5HT4 receptor has so far not been cloned (32). Of these newly discovered receptors, only the 5HT4, receptor has so far been investigated in some detail. These receptors are quite widely distributed in the brain and peripheral tissues where they are positively coupled to adenylate cyclase. In the brain, the 5HT4 receptors facilitate acetylcholine release and may play a role in peristalsis. It has been hypothesized that in the brain 5HT4 receptors may also play a role in facilitating cholinergic transmission and thereby have a potential role to play in presenting cognitive deficits which are associated with cortical cholinergic malfunction (5). The possible clinical significance of 5HT4 receptors must await the development of specific agonists and antagonists. So far, such compounds have not been developed.

Despite the dramatic advances which have taken place in the identification and characterisation of 5HT receptor sub-types, it is evident that many of the ligands used to characterise these receptor sub-types are not completely selective. It must also be emphasized that receptors are the products of genes which are therefore subject to genetic changes and, as a consequence, variability in physiological and pharmacological responsiveness. Thus affinity, potency and intrinsic activity of a drug at one receptor may vary depending on the time, species and receptor-effector coupling. It is already known, for example, that ipsapirone, buspirone, spiroxatrine and lysergic acid diethylamide may behave either as agonists or antagonists depending on the functional model being used to assess their

51 Vol 3. No 1 & 2. Spring and Summer 1996 JIUMS
TABLE 1. CLASSIFICATION OF CENTRAL
SEROTONIN RECEPTORS IN MAMMALIAN BRAIN

<table>
<thead>
<tr>
<th>RECEPTOR SUB-TYPE</th>
<th>5HT-1A</th>
<th>5HT-1B</th>
<th>5HT-1D</th>
<th>5HT-1E</th>
<th>5HT-1F</th>
</tr>
</thead>
<tbody>
<tr>
<td>5HT1-LIKE</td>
<td></td>
<td>cAMP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary messenger</td>
<td>-</td>
<td>cAMP</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Clones</td>
<td>Human</td>
<td>Rat</td>
<td>Human</td>
<td>Human</td>
<td>Human</td>
</tr>
<tr>
<td>Amines</td>
<td>421</td>
<td>386</td>
<td>377/390</td>
<td>365</td>
<td>366</td>
</tr>
<tr>
<td>Selective agonists</td>
<td>8-OHDPAT</td>
<td>CP93129</td>
<td>Sumatriptan</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Selective antagonists</td>
<td>Way 100135</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Radioligands</td>
<td>3H-8OHDPAT</td>
<td>125 IGTI</td>
<td>125 IGTI</td>
<td>3H-5HT</td>
<td>125 ILSD</td>
</tr>
</tbody>
</table>

CP-93129 = 5-hydroxy-3(4-R,1,2,5,6- tetrahydropryridly)-4-azarindole
8-OHDPAT = 8-hydroxy-2-(di)-n-propylaimino-tetralin
WAY 100135 = N-test-butyl-3-4 (2-methoxyphenylpiprazin-1-Y1-2-phenyl-Propanamide dihydrochloride)
GTI = 5-0-carboxamidomethylglucyl(125 I) tyrosinamide-tryptamine.

<table>
<thead>
<tr>
<th>RECEPTOR SUB-TYPE</th>
<th>5HT2A*</th>
<th>5HT2B*</th>
<th>5HT2C**</th>
<th>5HT3***</th>
<th>5HT4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary messenger</td>
<td>-</td>
<td>IP3/DG</td>
<td>-</td>
<td>Cation channel</td>
<td>cAMP</td>
</tr>
<tr>
<td>Clones</td>
<td>Human</td>
<td>Rat fundus</td>
<td>Human</td>
<td>Mouse</td>
<td>-</td>
</tr>
<tr>
<td>Amines</td>
<td>471</td>
<td>479</td>
<td>458</td>
<td>487</td>
<td>-</td>
</tr>
<tr>
<td>Selective agonists</td>
<td>-Methyl-</td>
<td>-methyl-</td>
<td>-methyl-</td>
<td>2-methyl-</td>
<td>5-methoxy-tryptamine</td>
</tr>
<tr>
<td>5HT</td>
<td>5HT</td>
<td>5HT</td>
<td>5HT</td>
<td>5-HT</td>
<td>Renzapride</td>
</tr>
<tr>
<td>Selective antagonists</td>
<td>Ketanserin</td>
<td>LYS3857</td>
<td>Mesulergine</td>
<td>Tropisetrone</td>
<td>GRII3808</td>
</tr>
<tr>
<td>Ritanserin</td>
<td>LYS3857</td>
<td>LYS3857</td>
<td>LYS3857</td>
<td>Granisetron</td>
<td>Ondansetron</td>
</tr>
<tr>
<td>Radioligands</td>
<td>3H-Ketanserin</td>
<td>3H-5HT</td>
<td>3H-mesulergine</td>
<td>3H-zacopride</td>
<td>3H-</td>
</tr>
<tr>
<td></td>
<td>GR113808</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
LY = 4-ISOPROPYL-7-METHYL-9-(2-HYDROXY-1 METHYLPROPYL CARBONYL-4,6,6A,7,8,9,10A-OCTAHYDRODIONODOL (4,3,FG).

GR 113808 = 1-(2-(METHYSULPHONYL-AMINO) ETHYL)-4-PIPERIDINYL METHYL-1-METHYL-IH INDOLE-3-CARBOXYLATE)

* 5HT2A previously called "5HT2" or "5HT D" receptor
** 5HT2C previously called "5HTC" receptor
*** 5HT3 previously called "5HTM" receptor

(Table 1 abridged from Humphrey et al., 1993)

Legend to Table 1.

8-OHDPAT = Dipropylamino-8-hydroxy-1,2,3,4-tetrahydroanaphylathylene
RU-24969 = 5-Methoxy-3-(1,2,3,6-tetrahydroxyridin-4-yl) IH indol.
MCPP = 1-)3 chlorophenyl piperazine
TFMPF = 1-(metrifluoromethylphenyl) piperazine
DOI = 1-(2,5-dimethoxy-1-iophenyl) 2-aminopropane
MDL 73005 = 8,2(2,3-dihydro-1,4-benzodioxin-2yl)
methylamino-ethyl-8-azaspirol (4,5) decan -7,9-dione
NAN 190 = 1-(2-methoxyphenyl) 4-(4(2-phthalimido) entyl-peierzine.
5-CT = 5-carboxamidotryptamine
ICI 169369 = (2-2(dimethylamino-ethylthio-3-phenylquinoline)
ICS 205-930 = (3-tropanyl)-IH-indole-2-carboxylic acid ester
DOM =2,5, dimethoxy-4-dimethylbenzene ethamine

(See reviews by Leysen, 1985; Fraser et al., 1990).

activity. A similar problem arises with intrinsic activity which is usually assumed to be a direct reflection of the pharmacological properties of the drug. It seems possible that the affinity can also be influenced by the nature of the genetically determined receptor-effector coupling and therefore tissue (and species) dependent. Such factors may help to explain why the identification and sub-classification of 5HT receptor sub-types is complex and often confusing.

This dilemma can be illustrated by the attempts being made to identify the functional role of 5HT receptor sub-types using ligands which are believed to be specific in their binding properties. Such
ligands may prove to be non-selective, more selective for and as yet unidentified 5HT receptor sub-type or more selective for non-5HT receptor site. Conversely several non-5HT ligands are known to bind to 5HT receptors with a high affinity. For example, the alpha 1 adrenoceptor antagonist WB4101, and the beta adrenoceptor antagonist pindolol, have a high affinity to 5HT1A receptors. Nevertheless, despite these cautions, there is a growing body of information which implicates different 5HT receptor sub-types in a variety of physiological and pharmacological responses and these will be briefly reviewed.

---

**Table 2. SEROTONIN RECEPTOR SUB-TYPES AND DISEASE STATES**

<table>
<thead>
<tr>
<th>PHYSiological or Pathological Condition</th>
<th>Serotonin Receptor Sub-Type Implicated</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Feeding behaviour 5HT1A agonists enhance food consumption in experimental animals. 5HT2 agonists decrease food consumption in experimental animals.</td>
<td></td>
</tr>
<tr>
<td>2. Thermoregulation 5HT1A agonists cause hypothermia in experimental animals. 5HT1B and 5HT2 agonists cause hyperthermia in experimental animals.</td>
<td></td>
</tr>
<tr>
<td>3. Sexual behaviour 5HT1A agonists both facilitate and inhibit sexual behaviour in male rats. 5HT1B agonists inhibit sexual behaviour in the male but facilitate the behaviour in the female rat.</td>
<td></td>
</tr>
<tr>
<td>4. Cardiovascular system 5HT1, 5HT2 and 5HT3 receptors maybe involved in the complex action of serotonin on blood pressure 5HT2 agonists appear to be hypertensive agents whereas the antagonists are hypotensives.</td>
<td></td>
</tr>
<tr>
<td>5. Sleep 5HT1A agonists delay the onset of REM sleep while 5HT2 antagonists suppress REM sleep.</td>
<td></td>
</tr>
<tr>
<td>6. Hallucinogenic activity Most &quot;classical&quot; hallucinogens such as LSD and mescaline are antagonists at 5HT2 receptors.</td>
<td></td>
</tr>
</tbody>
</table>
7. Antipsychotic activity

Many atypical neuroleptics (e.g. amperozide and risperidone) are 5HT2 receptor antagonists. In animals, 5HT3 antagonists have profiles similar to chronically active neuroleptics.

8. Anxiolytic activity

Several novel anxiolytics (e.g. buspirone, ipsapirone) are 5HT1A partial agonists.

5HT2 and 5HT3 antagonists have anxiolytic properties.

9. Depression

5HTA receptors are functionally sensitized by chronic antidepressant treatments in rats.

5HT2 receptor numbers are increased and activity decreased, in depression, return to control values in response to treatment.

Sleep

It has been known for some years that the functional activity of 5HT neurons in the brain changes dramatically during the sleep-wake arousal cycle (48). Thus from a stable, slow and regular discharge pattern during quiet wakening, neuronal activity gradually declines as the animal becomes drowsy and enters slow wave sleep. During rapid eye movement (REM) sleep, 5HT activity is totally supressed but in anticipation of wakening the neuronal activity returns to its basal level several seconds before the end of the REM episode. During arousal or wakening, the 5HT neuronal discharge pattern increases considerably above the quiet waking state (41).

Koella (45) has reviewed the evidence implicating the involvement of serotonin in the sleep-wake cycle but the involvement of specific serotonin receptor sub-types in sleep mechanisms is unclear. Experimental evidence suggests that 5HT1A agonists delays the onset of rapid eye movement (REM) sleep while 5HT2 antagonist suppress REM and have variable effects on non-REM sleep (56).

It must be emphasized that most studies of the relationship between the serotonergic system and sleep have been conducted in rats and therefore the relevance of such findings to man remains unproven. From such experimental studies, it has been shown that blockade of 5HT2 receptors increases the proportion of slow wave sleep and decreases the quantity of REM sleep (68). Whether this effect of 5HT2 antagonists can be ascribed to a specific effect on slow wave sleep is however, a matter of conjecture as any increase in time spent in one stage of sleep will be reflected in a decrease in the time spent in other stages of sleep. However, experimental evidence suggests that most drugs that alter serotonergic transmission reduce REM sleep (21). There is evidence that the 5HT2 antagonist
ritanserin improves sleep quality in those suffering from "jet-lag" (37). Which suggests that the 5HT2 receptors may be involved in adjusting the sleep-wake cycle to the photoperiod. Furthermore, experimental data suggest that activation of 5HT2 receptors may vary according to the sleep/wake cycle (20). Such findings suggest that 5HT2 receptors are involved in the regulation of circadian rhythms and the sleep-wake cycle. With regard to the overall role of 5HT in sleep, Koella (45) has postulated that serotonin may produce its various effects on sleep architecture by influencing cognition and vigilance.

Hallucinogenic activity
There is abundant experimental evidence to show that serotonin plays a major role in the mechanism of action of hallucinogens (42, for review), but it is presently unclear whether the actions of hallucinogens can be explained by their agonistic or antagonistic actions. LSD, for example, may behave either as an agonist or antagonist depending on the particular tissue, concentration and experimental condition, whereas the tryptamine type of hallucinogens usually act as agonists (30). Experimental evidence nevertheless suggest that the behavioural effects of a number of indole alkylamine (e.g. LSD-like) and phenylalkylamine (e.g. mescaline-like) hallucinogens can be attenuated by 5HT2A antagonists and that the potency of these classes of hallucinogens at 5HT2A (and possibly 5HT2C) sites correlate with their hallucinogenic potency in man (31). It seems unlikely however that all hallucinogens owe their activity to their potency in stimulating 5HT2A receptors; LSD and 5-methoxydimethyltryptamine for example interact with 5HT2C sites, while phenycyclidine may owe its hallucinogenic potency to and action on NMDA and a sub-class of sigma receptors (43). Nevertheless, the balance of evidence suggest that most "classical" hallucinogens like LSD, mescaline and psilocybin act as partial agonists on 5HT2A receptors.

Drug abuse
The role of 5HT in the control of alcohol intake has received considerable attention following the discovery that 5HT reuptake inhibitors reduce alcohol intake in alcohol dependent rats (39,53). Similar effects have been found for intra-cerebroventricular administered 5HT or its precursor 5HTP (60). Regarding the type of 5HT receptor involved, there is experimental evidence that the 5HT1A partial agonists buspirone and gepirone (12) are effective. Differences were found between the effects of the 5HT3 antagonist ondansetron and the 5HT2A/5HT2C antagonist ritanserin. Thus ondansetron reduces alcohol intake without effecting the alcohol preference of rats while ritanserin reduces both the alcohol
preference and intake (49). This suggests that, at least in rats, different population of 5HT receptors may be involved in alcohol intake and preference.

Regarding other types of drugs of abuse, the 5HT3 antagonist MDL 72222 has been shown to block place preference conditioning induced in rodents by morphine or nicotine without affecting the preference for amphetamine (44). It is possible that these effects of 5HT3 antagonists are associated with the reduction in dopamine release as it is well established that the rewarding effects of many drugs of abuse are due to increased dopaminergic activity in limbic regions (18). On the strength of the experimental findings, it has been proposed that 5HT3 antagonists might be useful to treat drug abuse in man (9). Only appropriate placebo controlled studies of 5HT3 antagonists will clarify the therapeutic value of such agents in different types of drug abuse.

Antipsychotic activity

Given the complexity of the serotonergic system and its interaction with multiple neurotransmitter systems in the mammalian brain, it is not surprising to find that 5HT plays a role in the aetiology of schizophrenia. Meltzer (50) has suggested that in schizophrenia a malfunction of the mechanism whereby 5HT modulates the release of dopamine (for example, due to the decreased inhibition by 5HT of the release of dopamine in the mesencephalon and frontal cortex) might contribute to the enhanced neocortical dopaminergic function which probably from the biochemical basis of the disease. The antipsychotic activity of atypical neuroleptics such as clozapine and risperidone may therefore lay in the normalization of the relationship between the malfunctioning 5HT and dopaminergic systems.

The novel antipsychotic drug clozapine has a very complicated neurochemical profile in that it has a high affinity for 5HT2A, 5HT2C, 5HT3, 5HT6 and 5HT7 receptors in addition to its action on D4 and D3 receptors (see 59). Risperidone likewise has a high affinity for 5HT2A receptors as well as acting as an antagonist of D2 receptor (51). Such drugs have received attention recently because of their reduced propensity to cause extrapyramidal side effects and for their efficacy in treating the negative symptoms of schizophrenia. These properties may partly reside in the antagonistic actions of the atypical neuroleptics on the various sub-populations of 5HT receptors of which the 5HT2A receptor may be of primary importance.

In experimental studies, many clinically effective neuroleptics have been shown to act as 5HT2A receptor antagonists (30). Studies on post-mortem brain from schizophrenic patients have shown that the
decrease in the number of 5HT2A receptors in the prefrontal cortex might be related to the disease process (52). It therefore seems unlikely that the antipsychotic activity of neuroleptics can be explained solely in terms of their action on 5HT2A receptors. Furthermore, no correlation exists between the average therapeutic doses of a neuroleptic and its affinity for 5HT2A receptors. It does seem possible, however, that several atypical neuroleptics such as amperozide, risperidone and possibly ritanserin do owe at least part of the pharmacological profile to their ability to inhibit 5HT2A receptors.

Following the discovery that selective 5HT3 antagonists reduce the behavioural effects of the infusion of dopamine into the nucleus accumbens, there has been considerable interest in the possible role of 5HT3 receptor antagonists as potential neuroleptic agents (33). This subject has been extensively reviewed by Costall and co-workers (14) and while there is a growing body of evidence to suggest that 5HT3 antagonists may be therapeutically valuable for the treatment of disorders of the gastrointestinal tract, as antiemetics and possibly anxiolytic agents, there is currently little evidence to suggest that such drugs are effective in the treatment of schizophrenia. The experimental studies of the 5HT3 antagonists on dopamine (D1) autoreceptors which may eventually offer new leads to the development of novel antipsychotic drugs has been the subject of recent mini reviews by Abbott (1) and Tricklebank (66).

Anxiolytic activity

Although the benzodiazepine anxiolytics primarily interact with the GABA receptor complex, there is ample experimental evidence to show that secondary changes occur in the turnover, release and firing of 5HT neurons as a consequence of the activation of the GABA-benzodiazepine receptor. Similar changes are observed in the raphe nuclei where a high density 5HT1A receptors occur (see 62). Such findings suggest that 5HT may play a key role in anxiety disorders.

Gardner (28) has reviewed the literature implicating the involvement of serotonin in anxiety. Undoubtedly one of the most important advances in this area has been the development of the azaspirodecanone derivatives buspirone, gepirone and ipsapirone as novel anxiolytics (see 65). All three agents produce a common metabolite, namely 1-(2-pyrimidinyl) piperazine or 1-PP, which may contribute to the anxiolytic activity of the parent compounds. It soon became apparent that these anxiolytic agents do not act via the benzodiazepine or GABA receptors but show a relatively high affinity for the 5HT1A sites; the 1-PP metabolite however only possesses a very low affinity for the 5HT1A site although it...
may contribute to the anxiolytic effect of the parent compound by acting as an alpha2 adrenoceptor agonist. In experimental studies, these atypical anxiolytics have mixed actions, behaving as agonists in some situations and antagonists in others. For this reason they are considered to be partial agonists at 5HT1A receptors, acting either as agonists on pre-synaptic 5HT1A receptors or antagonists on post-synaptic 5HT1A receptors (19).

In animal models of anxiety, 5HT2 receptor antagonists have been shown to be active. Ritalinserin appears to exhibit both anxiolytic and anxiogenic activity in different animal models (27). Nevertheless, in man, preliminary evidence suggests that ritalinserin is an effective anxiolytic agent (10), although Deakin et al. (17), in a placebo controlled trial of the 5HT2 antagonist ritalinserin, reported no differences in the Hamilton Anxiety and the Clinical Global Impression Scales between the drug treated and placebo treated patients.

The anxiolytic properties of 5HT3 receptor antagonists have been demonstrated in several animal models of anxiety (33). In these models, the 5HT3 antagonists mimic the anxiolytic effects of the benzodiazepines but differ from the latter in their lack of sedative, muscle relaxant and anticonvulsant action. These compounds appear to be extremely potent (acting in the ng-ug/kg range) and, providing the initial clinical finding of their anxiolytic activity is substantiated, this group of drugs could provide a valuable addition to the non-benzodiazepine anxiolytics. Thus experimental and clinical evidence suggest that 5HT1A receptor partial agonists, 5HT2 and 5HT3 antagonists may be useful and novel anxiolytic agents.

Aggression, panic attack and related disorders

The possible overlap between anxiety, depression, panic attack, aggression and obsessive compulsive disorders, and the involvement of serotonin in the symptoms of these disorders, has recently led to the investigation of various selective serotonin uptake inhibitors and selective 5HT receptor agonists/antagonists in the treatment of these conditions. In experimental studies, there is evidence that drugs such as eltoprazine, which binds with high affinity to 5HT1A, 5HT2B and 5HT2C sites, are active anti-aggressive agents, whereas selective 5HT1A agonists, and 5HT2 and 5HT3 antagonists are inactive (55). There is also preliminary evidence to suggest that selective serotonin uptake inhibitors such as fluoxetine reduce impulsive behaviour which may contribute to their therapeutic action in the treatment of obsessive compulsive disorders and possibly in reducing suicidal attempts.

Zohar and Insel (70) have suggested that
the symptoms of obsessive compulsive disorder are due to supersensitive 5HT1 type receptors and that the function of serotonin uptake inhibitors such as clomipramine, fluoxetine and the non-selective 5HT antagonist metergoline owe their efficacy to their ability to reduce the activity of these receptors. The effects of serotonin uptake inhibitors in the treatment of obsessive compulsive disorders has been critically reviewed by Zak et al (69).

It now seems generally accepted that the effects of anti-obessional drugs may be mediated by serotonergic mechanisms. The apparent hypersensitivity of obsessive compulsive patients to the trazodone metabolite m-chlorophenyl piperazine (MCCP, a non-selective 5HT1B, 5HT2C) and 5HT2 agonist) suggests that a diverse group of 5HT1 and 5HT2 receptors are involved (71). The efficacy of buspirone, a partial agonist of 5HT1A receptors in attenuating the obsessional symptoms (57) further suggests that 5HT1A receptors are also involved. As the 5HT re-uptake inhibitors such as fluoxetine and fluvoxamine are particularly effective in attenuating the obsessive symptoms following several weeks of administration, it may be argued that the therapeutic effect of such drugs lies in their ability to desensitize the supersensitive 5HT1-type receptors. Which of the 5HT1 receptors is specifically involved is unclear, but neuroimaging studies on patients with obsessive compulsive disorder implicates the striatum as the major brain region which is defective (4). The 5HT receptors in the striatum are of the 5HT1D and 5HT2 in man which may implicate these receptor sub-types specifically in the aetiology of the condition.

There is increasing evidence that selective serotonin uptake inhibitors are of value in the treatment of panic attack (61) and while the specific involvement of serotonin in the aetiology of the disease has yet to be established, there is experimental evidence which suggests that the 5HT2 receptors on the platelet membrane are hypoactive (7). Effective treatment with antidepressant or behaviour therapy results in a partial normalization of 5HT2 receptor responsiveness. Whether selective 5HT2 antagonists have any therapeutic value in the treatment of this disorder still awaits confirmation.

5HT Receptors and the anxiety disorders

Coplan and co-workers (11) have postulated that the neurological basis for the role of 5HT in anxiety disorders involves two major serotonergic pathways. The raphe projections to the brain stem and limbic system mediate the main inhibitory effects of 5HT whereas those projections for the raphe to the hypothalamus mediate the stimulatory endocrine effects of the
Serotonin receptors and their possible .......... B.E. Leonard

transmitter. Loss of serotonergic tone is postulated to be associated with depression and panic. This implies that panic attacks prefrontally involve the descending inhibitory pathways to the medullary centres which leads to the symptoms of suffocation frequently experienced by such patients. The non effectiveness of 5HT1A partial agonists such as buspirone in panic disorder may therefore be related to the inability of such drugs to suppress the consequent ventilatory "overdrive". By contrast depressive symptoms may be related to the loss of serotonergic tone in the ascending projections to the limbic and cortical regions of the brain. Such defects may be corrected by drugs such as the azaspirodecanes (ipsapirone, buspirone etc) and the antidepressants (tricyclics and selective serotonin reuptake inhibitors SSRI's) which activate the postsynaptic 5HT1A receptors in these regions.

With regard to generalized anxiety disorder (11) postulate that an overactivity of the stimulatory 5HT pathways occur. Drugs such as buspirone and ipsapirone are effective in such conditions because they stimulate the inhibitory 5HT1A auto receptors on the raphe nuclei and thereby reduce serotonergic function. It is noteworthy that the SSRI's often worsen anxiety initially because they temporarily enhance serotonergic function. Adaptive changes in the pre-and post synaptic 5HT receptors then occur leading to a reduction in the anxiety state.

Depression

Serotonin is believed to play a multi-functional role in depression which is to be anticipated from its involvement in the physiological processes of sleep, mood, vigilance, feeding and possibly sexual behaviour and learning all of which are derreranged to varying extents in severe depression. However, the involvement of precise serotonin receptor sub-types in depression, and in the action of antidepressants, is still far from clear. One approach to unravelling the changes in serotonin receptors in depression has been to study the effects of chronically administered antidepressants on serotonin receptor sub-types in rat brain. While there is evidence that most antidepressants show only a low affinity for the 5HT1 sites, there is experimental evidence to show that chronic antidepressant treatment results in a hypersensitivity of post-synaptic and a hyposensitivity of pre-synaptic 5HT1A receptors (34). In contrast to the 5HT1A receptors, many antidepressants from various chemical classes have a moderate affinity for 5HT2 receptors although there is no apparent correlation between the 5HT2 receptor affinity and the antidepressant potency (54).

Regarding the changes that occur in rat
cortical 5HT2 receptor density following chronic antidepressant and lithium treatment, there is unequivocal evidence that the number of receptors increase in response to chronic drug treatment although it must be emphasized that chronic ECS results in a decrease in the receptor number. Similarly in untreated depressed and panic patients, the density of 5HT2 receptors on the platelet membrane has been shown to be increased \(^{(7,8)}\). The number of receptors normalizes on effective, but not ineffective, treatment. Using the serotonin induced platelet aggregation response as a measure of the functional activity of 5HT2 receptors, it has been consistently shown that the 5HT2 receptor responsiveness is reduced in the untreated depressive but returns to control values following effective treatment irrespective of the nature of treatment \(^{(8,36)}\). Thus changes in 5HT2 receptor density and function appear to be disturbed in the depressed patient and return to control values only following effective treatment. The increase in the receptor number, and decrease in their responsiveness to serotonin, in the untreated depressed patient may suggest an abnormality in the coupling mechanism between the receptor site and the phosphatidylinositol second messenger system that brings about the platelet shape change underlying aggregation.

Deaking et al \(^{(17)}\) have suggested that depression could arise from a pathological enhancement of 5HT2 receptor function. This view would concur with the observations that the functional activity of 5HT2 receptors on the platelet membrane is enhanced in depression \(^{(8,36)}\) and the increase in the density of 5HT2 receptors in the frontal cortex of brains from suicide victims \(^{(3,63)}\). Deakin et al \(^{(17)}\) hypothesize that enhanced 5HT2 receptor function is associated primarily with anxiety, a common feature of depression, and that the increased activity of the 5HT2 receptors results in an attenuation of the functioning of 5HT1 receptors thereby resulting in the symptoms of depression. Whether this change in the activity of 5HT1 receptors is due to direct effect of the altered 5HT2 receptor function is uncertain. There is evidence that hypercortisolaemia, which is a characteristic feature of depression, reduces the activity of these receptors probably through central glucocorticoid type 2 receptors \(^{(17)}\). Clearly further research is needed to determine the precise interaction between the 5HT2 and 5HT1 receptor types.

More recently, \(^{(11)}\) have speculated that the 5HT1B/1D receptors may have a role to play in depression and in the mode of action of antidepressants. These receptors appear to be located pre-synaptically where they control the release of 5HT; in experimental studies the non-selective 5HT1 antagonist methiotherpin has antidepressant properties.
Serotonin receptors and their possible ...... B.E. Leonard

(47 unpublished). Thus it may be speculated that the 5HT1B/ID receptors are supersensitive in depression, thereby leading to a reduced intersynaptic concentration of 5HT with a consequent increase in the number of post-synaptic 5HT2 receptorsites. However, only, the development of highly selective 5HT1B/ID antagonists will enable this hypothesis to be tested.

Although the precise mechanism whereby antidepressant produce their therapeutic effects is incompletely understood, there is a growing body of evidence to suggest that serotonin receptors, particularly of the 5HT1A and 5HT2 sub-type, play a role in their actions. Only the 5HT2 receptors has, so far, been convincingly demonstrated to be malfuctional in depression and to be normalized following effective treatment. Leonard (46) has reviewed the role of biological markers of 5HT receptors in depression elsewhere.

Conclusion

It is evident that serotonin is involved in a variety of physiological processes and that disturbances of serotonergic function may be of importance in the aetiology of many gastrointestinal, cardiovascular and central nervous system diseases. The existence of sub-types of serotonin receptors and the impetus that this has given to the development of drugs with selective actions on these receptor sub-types is already leading to the development of new therapeutic agents. Evaluation of the functional status of serotonin receptor sub-types in psychiatric and neurological diseases may be of future importance in the diagnosis and assessment of treatment response in such patients. In this regard, the development of serotonin receptor probes coupled with such techniques as positron emission tomography may be of considerable importance in diagnosis in the future (15).

To-date, at least 4 major sub-types of serotonin receptor have been described and a major advance has been made with the isolation of genomic clones for these receptor sub-types. This has been reviewed by (32,35,40). We now await the further development of selective ligands for all the serotonin receptor subtypes which may ultimately lead to a better understanding of the functional significance and clinical relevance of serotonin receptors in health and disease.
REFERENCES


24) Engel, G., Hoyer, D., Kalkman, H.O.


17, 251-260.


Serotonin receptors and their possible 

Distribution of serotonin-immuno-reactivity in the central nervous system of the rat cell bodies and terminals. Neuroscience, 6, 557-618.


JIUMS